Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Work
Year: 2017
Type: article
Abstract: In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after t... more
Source: New England Journal of Medicine
Authors Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos +35 more
Institutions The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, Washington University in St. Louis, University of Miami, Stanford University +19 more
Cites: 35
Cited by: 4,730
Related to: 10
FWCI: 190.3
Citation percentile (by year/subfield): 100
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze